PMID- 24756806
OWN - NLM
STAT- MEDLINE
DCOM- 20140908
LR  - 20211203
IS  - 0080-0015 (Print)
IS  - 0080-0015 (Linking)
VI  - 201
DP  - 2014
TI  - Temsirolimus.
PG  - 393-403
LID - 10.1007/978-3-642-54490-3_24 [doi]
AB  - Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase 
      mammalian target of rapamycin (mTOR) and consequently blocks the translation of 
      cell cycle regulatory proteins and prevents overexpression of angiogenic growth 
      factors. It has been found to have antitumour activity in patients with relapsed 
      or refractory mantle cell lymphoma (MCL). In addition, patients with advanced 
      renal cell carcinoma (RCC) and a poor prognosis who received a once-weekly 
      intravenous (IV) infusion of temsirolimus 25 mg experienced significant survival 
      benefits compared with patients receiving standard interferon-alpha (IFN-alpha) therapy 
      in a large phase III clinical study. In this study, median overall survival was 
      10.9 versus 7.3 months and objective response rates were 8.6% in temsirolimus 
      recipients versus 4.8% IFN-alpha recipient group. Temsirolimus monotherapy recipients 
      experienced significantly fewer grade 3 or 4 adverse events and had fewer 
      withdrawals for adverse events than patients receiving IFN-alpha. The role of 
      temsirolimus in sequential and combination therapy is yet to be found.
FAU - Schulze, Michael
AU  - Schulze M
AD  - Department of Urology SLK-Klinikum Heilbronn, Teaching Hospital of the University 
      of Heidelberg, Am Gesundbrunnen 20, 74074, Heidelberg, Germany.
FAU - Stock, Christian
AU  - Stock C
FAU - Zaccagnini, Massimo
AU  - Zaccagnini M
FAU - Teber, Dogu
AU  - Teber D
FAU - Rassweiler, Jens J
AU  - Rassweiler JJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Recent Results Cancer Res
JT  - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans 
      les recherches sur le cancer
JID - 0044671
RN  - 0 (Antineoplastic Agents)
RN  - 624KN6GM2T (temsirolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Sirolimus/*analogs & derivatives/therapeutic use
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
EDAT- 2014/04/24 06:00
MHDA- 2014/09/10 06:00
CRDT- 2014/04/24 06:00
PHST- 2014/04/24 06:00 [entrez]
PHST- 2014/04/24 06:00 [pubmed]
PHST- 2014/09/10 06:00 [medline]
AID - 10.1007/978-3-642-54490-3_24 [doi]
PST - ppublish
SO  - Recent Results Cancer Res. 2014;201:393-403. doi: 10.1007/978-3-642-54490-3_24.